Clinical trials: B-Cell Pediatric ALL
Acute Lymphoblastic Leukemia
Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL
This is a single arm, open-label, multi-center, phase II study to determine the activity and the safety of a therapeutic strategy that allows a second CARCIK-CD19 cells infusion, driven by the status of disease from one month…
- Trial name
- NCT05252403
- Testing
- PTG-CARCIK-CD19
- Where
- 2 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
- Trial name
- NCT07134088
- Testing
- Blinatumomab
- Where
- 5 sites in United States, Japan
- Volunteers
- 104 people
- Sponsor
- Amgen
B Cell Precursor Acute Lymphoblastic Leukemia, Pediatric
NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL
The goal of this clinical trial is to determine whether pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients with negative deep minimal residue disease (MRD) can benefit from blinatumomab treatment.
- Conditions
- B Cell Precursor Acute Lymphoblastic Leukemia, Pediatric, Minimal Residual Disease, Next Generation Sequencing (NGS)
- Trial name
- NCT06763302
- Testing
- Blinatumomab
- Volunteers
- 1,220 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART C (NCT05745714)
- Testing
- Ruxolitinib, Venetoclax, Dexamethasone
- Where
- 33 sites in Austria, Belgium and 12 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Study of Out of Specification for Tisagenlecleucel
This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved…
- Trial name
- NCT04094311
- Testing
- CTL019
- Where
- 55 sites in Canada, Japan
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphoma
Interferon Alfa in Treating Children With HIV-Related Cancer
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating children with an HIV-related cancer including leukemia, non-Hodgkin's…
- Conditions
- Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00002621
- Testing
- recombinant interferon alfa
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 8 people
- Sponsor
- Children's Oncology Group
Allogeneic Haematopoietic Stem Cell Transplantation
Vaccination of Children Following Allogeneic Stem Cell Transplantation
The purpose of this study is to determine the immunogenicity and tolerability of the DTaP-IPV-HBV/Hib combination vaccine Infanrix hexa and the heptavalent pneumococcal conjugate vaccine Prevenar in pediatric recipients of…
- Trial name
- NCT00169728
- Testing
- DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa, heptavalent pneumococcal conjugate vaccine, Prevenar
- Where
- 11 sites in Germany
- Volunteers
- 53 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Fever, Sweats, and Hot Flashes, Infection
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
RATIONALE: Recombinant human mannose-binding lectin (MBL) may be effective in preventing infection in young patients with fever and neutropenia receiving chemotherapy for blood disease or cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00886496
- Testing
- recombinant human mannose-binding lectin
- Where
- 3 sites in United States
- Sponsor
- Enzon Pharmaceuticals, Inc.
NHL, Large Cell Lymphoma
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Background: One type of cancer therapy takes blood cells from a person, changes them in a lab, then gives the cells back to the person.
- Conditions
- NHL, Large Cell Lymphoma, Follicular Lymphoma, ALL
- Trial name
- NCT02315612
- Testing
- CD22-CAR
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- National Cancer Institute (NCI)
Grade B aGVHD, Grade C aGVHD
A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
The study plans to treat at least 60 pediatric participants, male and female, between the ages of 2 months and 17 years inclusive with aGVHD following allogeneic hematopoietic stem cell transplant (HSCT) that has failed to…
- Conditions
- Grade B aGVHD, Grade C aGVHD, Grade D aGVHD
- Trial name
- NCT02336230
- Testing
- remestemcel-L
- Where
- 20 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mesoblast, Inc.
Relapse/Refractory B-cell Acute Lymphoblastic Leukemia
Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
The goal of this clinical trial is to evaluate the safety and efficacy of CD19 CAR-T cells in pediatric patients of all genders, aged 2 to 18 years, with relapsing or refractory B cell acute lymphoblastic leukemia (r/r B-ALL).
- Trial name
- NCT06635330
- Testing
- anti-CD19 CAR T cell therapy
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Kara Yakhteh Tajhiz Azma Company
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
This pilot study examines the safety and efficacy of anti-CD19 CAR T cells manufactured on-site in children and young adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Acute Lymphoblastic Leukemia With Failed Remission
- Trial name
- NCT05779930
- Testing
- CD19 specific Chimeric Antigen Receptor T Cell
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nationwide Children's Hospital
B Acute Lymphoblastic Leukemia
Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic Leukemia
This study aimed to investigate the performance of next-generation sequencing (NGS) techniques measuring immunoglobulin heavy chain (IgH)-variable, diversity, and joining (V[D]J) clonal rearrangements （IgH-V[D]J NGS） compared…
- Trial name
- NCT04977895
- Testing
- Minimal residual disease (MRD) monitoring
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Sun Yat-sen University
Acid Sphingomyelinase Deficiency (ASMD), Niemann Pick Disease
National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children
The goal of this study is to describe the natural history of ASMD in adult and paediatric patients with or without specific treatment in order to assess the impact of the disease on their daily lives and quality of life.
- Trial name
- FASMD (NCT06985212)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Wladimir MAUHIN, Dr
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological…
- Conditions
- Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
- Trial name
- NCT05086315
- Testing
- SAR443579
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 101 people
- Sponsor
- Sanofi
Lymphoblastic Leukemia, Acute, Childhood
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated cytokine release syndrome safety events in pediatric patients with CD19 expressing…
- Trial name
- NCT02906371
- Testing
- Tocilizumab, CART 19
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Pennsylvania
Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, in Relapse
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children
The investigators will conduct a phase II clinical trial of autologous murine anti-CD19 chimeric antigen receptor T cells treating refractory or relapsed B acute lymphoblastic leukemia children in Beijing Boren Hospital.
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT04325841
- Testing
- Murine autologous anti-CD19 chimeric antigen receptor T cells
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Beijing Boren Hospital
Acute Lymphoblastic Leukemia, Pediatric
MRD Detection by NGS in Pediatric B-ALL
This retrospective analysis aims to investigate pediatric patients with B-cell acute lymphoblastic leukemia who were detected for minimal residual disease (MRD) using next-generation sequencing (NGS).
- Trial name
- NCT05973032
- Testing
- MRD
- Where
- China
- Volunteers
- 430 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Lymphoma
Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and using drugs in different ways may kill more tumor cells.
- Trial name
- NCT00002691
- Testing
- filgrastim, asparaginase, cyclophosphamide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia, Pediatric, ALL, Infants
Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
The innovation of this protocol is the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.
- Trial name
- NCT05029531
- Testing
- the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology